Key points from article :
The investment firm Prima Materia has made its third startup bet: on a longevity company.
It invested €10m into Epiterna, a Swiss startup working on slowing ageing.
Epiterna is using drugs and chemical compounds which are already approved....to develop products that could be used within years, not decades.
“We want our therapies to be simple to use and accessible to anyone,” - Ocampo.
“Small-molecule drugs are easier to manufacture, distribute and use, making them more affordable and accessible to anyone.”
Testing its therapies on a series of organisms from yeast to mice to assess the impact on health and lifespans.
Plans to run clinical trials on bigger animals, like dogs, which could happen as soon as next year in Europe.
Treatments for humans will come further down the line.
Regulatory approval for these therapies could be a major hurdle, as not everyone considers ageing a disease.
Epiterna has 15 employees and several open roles; it’s hiring for a scientist and regulatory affairs specialist, among others.
